OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Karmali Discusses Toxicites Associated With CAR T-Cell Therapies

October 20th 2017

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the toxicities associated with the use of chimeric antigen receptor (CAR) T-cell therapies.

Dr. Harrison on the Possibility of Nivolumab Plus Ipilimumab Becoming the New IL-2

October 20th 2017

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses the possibility of nivolumab (Opdivo) plus ipilimumab (Yervoy) becoming the new interleukin-2 (IL-2).

Dr. Berry on the Differences Between LHRH Antagonists and Agonists

October 19th 2017

William R. Berry, MD, medical oncologist, Duke University, talks about the differences between luteinizing hormone-releasing hormone (LHRH) antagonists and agonists.

Dr. Gold on the Current State of HPV-Related Head and Neck Cancer

October 19th 2017

Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses the current state of human papilloma virus (HPV)-related head and neck cancer.

Dr. Young on Using Vitamin K Antagonists in Children With Cancer

October 19th 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses using vitamin-K antagonists in children with cancer.

Dr. Hoffman-Censits Discusses Immunotherapy in Bladder Cancer

October 19th 2017

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.

Dr. Karmali on FDA Approval of KTE-C19 in Non-Hodgkin Lymphoma

October 19th 2017

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.

Dr. Epperla Discusses the Current Treatment of MCL

October 18th 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the current treatment landscape of patients with mantle cell lymphoma.

Dr. Maloney Discusses Excitement With CAR T-Cell Therapy

October 18th 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, Washington, discusses excitement with CAR T-cell therapy.

Dr. Shah Discusses Autologous Transplant in MCL

October 18th 2017

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).

Expert Discusses Improving MRI Testing for Prostate Cancer

October 18th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses improving MRI testing for patients with prostate cancer.

Dr. Zandberg on Biomarker Development in Head and Neck Cancer

October 18th 2017

Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.

Dr. Zandberg on the Role of Immunotherapy in Head and Neck Cancer

October 18th 2017

Dan Zandberg, MD, assistant professor of medicine, University of Maryland School of Medicine, discusses the role of immunotherapy in head and neck cancer.

Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma

October 18th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.

Dr. Bosse on the Quality of Life With VEGF Plus Radium-223

October 18th 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

Dr. Gradishar Discusses Dual HER2-Targeting in Breast Cancer

October 18th 2017

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.

Dr. Hope on the Detection Sensitivity of PSMA-PET Scanning

October 17th 2017

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco, discusses the detection sensitivity of PSMA-PET scanning.

Dr. Young Discusses Using Anticoagulants in Children With Cancer

October 17th 2017

Dr. Wierda Discusses Sequencing New Agents in CLL

October 17th 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing new agents in chronic lymphocytic leukemia.

Dr. Awan Discusses Challenges With Ibrutinib in CLL

October 16th 2017

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses challenges with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.